Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP:ALPMF)

13.00 -0.05 (-0.38%)
Streaming Delayed Price Updated: 3:55 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma Inc

< Previous 1 2 Next >
News headline image
Astellas' Menopause Drug Under FDA Review ↗
 
Via Benzinga
News headline image
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say ↗
 
Via Benzinga
News headline image
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Sutro Biopharma Stock Surges On Cancer Treatment Pact ↗
 
Via Benzinga
News headline image
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies ↗
 
Via Benzinga
News headline image
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer ↗
The  
Via Benzinga
News headline image
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial ↗
 
Via Benzinga
News headline image
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing ↗
Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor... 
Via Benzinga
News headline image
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients ↗
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (... 
Via Benzinga
News headline image
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact ↗
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... 
Via Benzinga
News headline image
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan ↗
Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically... 
Via Benzinga
News headline image
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold ↗
Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics... 
Via Benzinga
News headline image
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial ↗
Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in... 
Via Benzinga
News headline image
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat ↗
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
News headline image
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial ↗
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease... 
Via Benzinga
News headline image
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer ↗
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat... 
Via Benzinga
News headline image
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-... 
Via Benzinga
News headline image
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics ↗
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and... 
Via Benzinga
Topics Regulatory Compliance
News headline image
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold ↗
In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of... 
Via Benzinga
News headline image
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat ↗
FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company’s anemia treatment in chronic kidney... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.